Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 69 of 114

  1. Nilotinib

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  2. Nilotinib (AMN107)

    Novartis Pharmaceuticals

    Gastrointestinal Stromal Tumor (GIST)

    phase 3 small molecule completed

    1 trial

  3. Nimenrix

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    1 trial

  4. Nimotuzumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  5. Nimotuzumab

    Praxis Precision Medicines

    Pancreatic Cancer, Advanced or Metastatic

    phase 3 small molecule completed

    1 trial

  6. Nintedanib

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  7. Nintedanib

    Boehringer Ingelheim

    Lung Diseases, Interstitial

    phase 3 small molecule completed

    1 trial

  8. Nipocalimab

    Janssen Cilag International NV

    Sjogrens Syndrome

    phase 3 small molecule active

    1 trial

  9. Niraparib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  10. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  11. Niraparib tosylate monohydrate + abiraterone... for Prostate Cancer

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  12. NiuBangZi pill or NiuBangZi pill placebo

    Universal Integrated

    Niu Bang Zi Pill

    phase 3 small molecule active

    1 trial

  13. Nivolumab

    Bristol-Myers Squibb

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  14. Nivolumab

    Bristol-Myers Squibb

    Bladder Cancer

    phase 3 mab completed

    1 trial

  15. Nivolumab

    Ono Pharmaceutical Co.,

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  16. Nivolumab

    Shanghai Reinovax Biologics Co.,LTD

    Metastatic Kidney Cancer

    phase 3 small molecule active

    1 trial

  17. Nivolumab

    Bristol-Myers Squibb

    Head and Neck Cancer

    phase 3 mab completed

    1 trial

  18. Nivolumab

    Nektar Therapeutics UK Limited

    Bladder Cancer

    phase 3 mab completed

    1 trial

  19. Nivolumab

    Bristol-Myers Squibb

    Brain Neoplasms

    phase 3 small molecule completed

    1 trial

  20. Nivolumab

    Bristol-Myers Squibb

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  21. Nomlabofusp, Placebo to Nomlabofusp

    Larimar Therapeutics

    Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.

    phase 3 small molecule active

    1 trial

  22. Normal Saline

    The First People's Hospital of Lianyungang

    Postoperative Sleep Disturbance

    phase 3 small molecule active

    1 trial

  23. Nucresiran

    Alnylam Netherlands B.V.

    Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

    phase 3 small molecule active

    1 trial

  24. Nucresiran

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis With Cardiomyopathy

    phase 3 small molecule active

    1 trial

  25. NurOwn® (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 mab completed

    2 trials

  26. Nutritional supplements

    United Therapeutics Europe Ltd

    Low Birth Weight

    phase 3 small molecule completed

    1 trial

  27. OAV101

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 gene therapy completed

    1 trial

  28. OBEZ-302

    Lacuna Pharma Pty Ltd

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  29. OBEZ-303

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  30. OBI-1

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  31. OBI-1

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  32. OBI-822-011

    Lacuna Pharma Pty Ltd

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  33. OBINUTUZUMAB, RITUXIMAB

    Pari Pharma GmbH

    Idiopathic nephrotic syndrome (INS)

    phase 3 small molecule active

    1 trial

  34. OCA 5MG IR +BZF 400 MG SR

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  35. OCUS-Mode-CT-V1

    Elan Pharma International

    Myopia

    phase 3 small molecule active

    1 trial

  36. OFC Infusion

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 small molecule completed

    1 trial

  37. OLAPARIB

    AstraZeneca

    Platinum Sensitive Relapsed Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  38. ONO-4059-17

    Lacuna Pharma Pty Ltd

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  39. OP-1250-301

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  40. OP-1250-302

    Olema Pharmaceuticals

    ER+, HER2- Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  41. OP-LIPC02

    Lacuna Pharma Pty Ltd

    Recurrent herpes labialis (RHL)

    phase 3 small molecule active

    1 trial

  42. OP0595-5

    Lacuna Pharma Pty Ltd

    Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  43. OP0595-6

    Lacuna Pharma Pty Ltd

    Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)

    phase 3 small molecule active

    1 trial

  44. OPC-262

    KYOWA KIRIN AUSTRALIA PTY LTD

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  45. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    oesophageal cancer

    phase 3 small molecule active

    1 trial

  46. ORAVESCENT Fentanyl Citrate

    Teva Pharma GmbH

    Chronic Neuropathic Pain

    phase 3 small molecule completed

    1 trial

  47. ORAVESCENT Fentanyl Citrate

    Teva Pharma GmbH

    Chronic Low Back Pain

    phase 3 small molecule completed

    1 trial

  48. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.